A Virtual Reality Tour of Nonstatin LDL-C-lowering Agents that Decrease Cardiovascular Risk for Patients with Persistent Hypercholesterolemia
Henry Ginsberg, MD
Irving Professor of Medicine
Associate Dean of Clinical and Translational Research
Columbia College of Physicians and Surgeons
New York, NY
This case-based enduring activity will cover the long-term treatment and management of cardiovascular disease (CVD) due to hypercholesterolemia.
This activity is intended for lipidologists, cardiologists, endocrinologists, and other healthcare professionals involved in the management of patients at high risk for cardiovascular disease (CVD) due to hypercholesterolemia.
After completing the CME activity, learners should be better able to:
- Review evidence demonstrating that lowering LDL-C can reduce the risk for CVD in patients with persistently elevated cholesterol levels
- Discuss the latest clinical trial data available on nonstatin LDL-C–lowering agents and their position in treatment regimens for patients with elevated LDL-C levels
- Describe best practices for detection and management of persistently elevated LDL-C levels in patients at high-risk for CVD
- Explain the pharmacoeconomic data on the use of nonstatin lipid lowering drugs and their managed care implications
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the long-term treatment and management of patients with CVD.
1.0 ANCC Contact Hour(s)
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME)
Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Henry Ginsberg, MD: In the past 6 years, Dr. Ginsberg has received consulting fees from Amgen, AstraZeneca, Kowa, Merck, Esperion, Regeneron, Resverologix, and Sanofi. He has also received contracted research support from Amgen, Genzyme, Merck, Regeneron, and Sanofi.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Chris Drury, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Melissa Johnson, Sr. Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, Dr. Ginsberg may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at email@example.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
RELEASE DATE: October 15, 2018
EXPIRATION DATE: October 15, 2019
Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.